MedTrace Logo

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

NCT06941129 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-29

No results posted yet for this study

Summary

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Conditions

  • Systemic Lupus Erythematosus
  • Systemic Sclerosis (SSc)
  • Inflammatory Myopathy
  • ANCA-Associated Vasculitis (AAV)
  • Connective Tissue Disease-Associated Thrombocytopenia
  • SLE-ITP

Interventions

BIOLOGICAL

UCAR T-cell

universal allogeneic anti-CD19/BCMA CAR T-cells

Sponsors & Collaborators

  • Shanghai Xiniao Biotech Co., Ltd.

    collaborator INDUSTRY

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-11
Primary Completion
2028-02-18
Completion
2028-03-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06941129 on ClinicalTrials.gov